Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
101 hedge funds and large institutions have $236M invested in Regulus Therapeutics in 2016 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 30 reducing their positions, and 17 closing their positions.
810% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $1.11M
20% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 30
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
2% less funds holding
Funds holding: 103 → 101 (-2)
21% less capital invested
Capital invested by funds: $299M → $236M (-$62.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
Top Sellers
RGLS Hedge Fund Activity: Q1 2016 in Review
101 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2016, worth a combined $236M — down 21% from $299M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RGLS and 16 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 36 added.
The largest buyer was Capital World Investors, adding an estimated $10.1M. The largest seller was RA Capital Management, cutting an estimated $16.2M.
- 101 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2016, down from 103 in Q4 2015.
- Funds reported $236M of Regulus Therapeutics stock for Q1 2016, down 21% quarter-over-quarter.
- 16 funds opened new Regulus Therapeutics positions in Q1 2016 and 17 closed out, a net change of -1 holder.
- The largest Regulus Therapeutics buyer in Q1 2016 was Capital World Investors, an estimated $10.1M added.
- The largest Regulus Therapeutics seller in Q1 2016 was RA Capital Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q1 2016.